Findings

What do systematic reviews say?

6 questions · 6 findings · 3 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%

Aldosterone antagonists vs placebo or usual care

Hyperkalaemia · people with chronic kidney disease requiring dialysis

Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).

1 finding from 1 review

Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
RR 1.41 [0.72, 2.78]
9 studies · 981 participants
Low

Aldosterone antagonists vs placebo or usual care

Hyperkalaemia · proteinuric CKD

Aldosterone antagonists probably leads to higher hyperkalaemia compared with placebo or standard care (moderate certainty).

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
RR 2.17 [1.47, 3.22]
17 studies · 3001 participants
Moderate

CHRONIC: ACEi or ARB vs placebo

Hyperkalaemia · heart failure with chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CHRONIC: Beta‐blockers vs placebo

Hyperkalaemia · heart failure with chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aldosterone antagonists vs placebo

Hyperkalaemia · heart failure with chronic kidney disease

CHRONIC: Aldosterone antagonists may leads to higher hyperkalaemia compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
RR 2.91 [2.03, 4.17]
3 studies · 826 participants
Low

ACUTE: Serelaxin vs placebo

Hyperkalaemia · heart failure with chronic kidney disease

It is very uncertain whether ACUTE: Serelaxin changes hyperkalaemia compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
RR 1.08
1 study · 234 participants
Very low